Benepali etanercept and Flixabi infliximab biosimilar news

Studies conducted by Biogen comparing biosimilar autoimmune drugs Benepali etanercept (SB4) and Flixabi infliximab (SB2) to Enbrel etanercept and Remicade infliximab, respectively, showed that the two biosimilars could lead to "substantial cost savings" in European countries. The study used a budget-impact model estimating cost-saving potential over a three-year period for all approved indications.

Projected savings of Benepali vs. Enbrel were £14.2-£18.9 million ($17.7-$23.6 million) in the U.K.; €25.8-€51.5 million ($27.7-$55.3 million) in France; €31.5-€63 million ($33.8-$67.6 million) in Italy; and €15.4-€30.7 million ($16.5-$33 million) in Sweden. Projected savings of Flixabi vs. Remicade were £19.8-£66 million ($24.7-$82.3 million) in the U.K.; €41.5-€103.7 million ($44.5-$111.3 million) in France; and €9.3-€31.4 million ($10-$33.7 million) in Italy. Data were presented last month at the International Society For Pharmacoeconomics and Outcomes Research meeting in Vienna...